---
title: "Charles Rhyee Reiterates Buy on Icon, Lifts Price Target to $197 on Earnings Acceleration and Margin Expansion Confidence"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290752024.md"
description: "TD Cowen analyst Charles Rhyee reiterated a Buy rating on Icon, raising the price target from $164 to $197. The upgrade reflects confidence in earnings acceleration by 2027, driven by robust new business trends with book-to-bill ratios above 1.3x and healthy demand across pharmaceutical and biotech sectors. Additionally, Rhyee anticipates steady margin expansion through 2026 due to a favorable mix of higher-margin direct fee work and cost-efficiency measures."
datetime: "2026-06-25T00:05:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290752024.md)
  - [en](https://longbridge.com/en/news/290752024.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290752024.md)
---

# Charles Rhyee Reiterates Buy on Icon, Lifts Price Target to $197 on Earnings Acceleration and Margin Expansion Confidence

In a report released yesterday, Charles Rhyee from TD Cowen assigned a Buy rating on Icon, with a price target of $197.00.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Charles Rhyee has given his Buy rating due to a combination of factors that, in his view, set Icon up for meaningful earnings acceleration by 2027. He highlights robust new business trends, with book-to-bill ratios above 1.3x in key fee-based areas, along with healthy demand across large pharmaceutical companies, biotech, and mid-sized clients that supports a stronger medium-term growth profile.

Rhyee also points to management’s confidence in steady margin expansion through 2026, driven by a more favorable mix of higher‑margin direct fee work versus pass‑throughs, a better balance of functional service models, and ongoing cost-efficiency measures, which together should lift profitability. Reflecting this improved outlook, he raises his price target from $164 to $197, reinforcing his view that the current share price does not yet fully reflect the company’s earnings potential and operating leverage.

### Related Stocks

- [ICLR.US](https://longbridge.com/en/quote/ICLR.US.md)

## Related News & Research

- [ICON Restructures Debt and Divests Symphony Ahead of Note Maturities](https://longbridge.com/en/news/294376596.md)
- [Clinical research firm ICON's Q2 revenue rises 1.2%, beats analyst estimates](https://longbridge.com/en/news/294260888.md)
- [ICON faces expanded US securities class action, adds CFO and ex-employee as defendants](https://longbridge.com/en/news/294372002.md)
- [ICLR: Q2 2026 delivered $2,063m revenue, 15.9% adjusted EBITDA margin, and strong business wins](https://longbridge.com/en/news/294275599.md)
- [ICON partners with Anthropic to deploy Claude AI across clinical trial operations](https://longbridge.com/en/news/294054355.md)